Vitamin C Enhances the Effect of Etoposide to Inhibit Human Prostate Cancer Growth in vitro
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Etoposide (Eto) is chemotherapeutic compounds that is currently used in the treatment of metastatic prostate cancer but new therapeutic agents are needed for the treatment of androgen-independent prostate cancer. The objective of the present study was to determine whether vitamin C (VC), the antioxidant, plays a role in regulating the growth of prostate cancer cell lines and whether VC has synergistic effect to tumor cell killing by chemotherapeutic drugs. Androgendependent LNCaP and androgen-independent DU-145 prostate cancer cell lines were used in this study. Both cells presented increase of dose- and time-dependent cytotoxicity in Eto-treated cultures. The combined treatment with Eto and VC significantly increased the percentage of apoptotic cells compared to Eto-treated cells (p⁄0.05). The present findings demonstrated that VC inhibited the growth of prostate cancer cell lines by Eto-mediated cytotoxicity and induced apoptosis. These results suggest that the chemotherapeutic effect of Eto on prostate cancer can be enhanced by VC.
Abstract
Etoposide (Eto) is chemotherapeutic compounds that is currently used in the treatment of metastatic prostate cancer but new therapeutic agents are needed for the treatment of androgen-independent prostate cancer. The objective of the present study was to determine whether vitamin C (VC), the antioxidant, plays a role in regulating the growth of prostate cancer cell lines and whether VC has synergistic effect to tumor cell killing by chemotherapeutic drugs. Androgendependent LNCaP and androgen-independent DU-145 prostate cancer cell lines were used in this study. Both cells presented increase of dose- and time-dependent cytotoxicity in Eto-treated cultures. The combined treatment with Eto and VC significantly increased the percentage of apoptotic cells compared to Eto-treated cells (p⁄0.05). The present findings demonstrated that VC inhibited the growth of prostate cancer cell lines by Eto-mediated cytotoxicity and induced apoptosis. These results suggest that the chemotherapeutic effect of Eto on prostate cancer can be enhanced by VC.
참고문헌 (31)
- Berruti A, "Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5 year follow-up", Urol Oncol, 23, pp.1~7 (2005)
- Borner MM, "Drug induced apoptosis is not necessarily dependent on macromolecular synthesis of proliferation in the p53 negative human prostate cancer cell line PC-3", Cancer Res, 55, pp.2122~2128 (1995)
- Diaz M, "Management of androgen-independent prostate cancer", Cancer Control, 11, pp.364~373 (2004)
- Eastman A, "Activation of programmed cell death by anticancer agents: cisplatin as a model system", Cancer Cells (Cold Spring Harbor, 2, pp.275~280 (1990)
- English HF, "Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration", Prostate, 15, pp.233~250 (1989)
- Frost PJ, "Sensitization of immunoresistant prostate carcinomacell lines to fas", fas ligand-mediated killing by cytotoxic lymphocytes: independence of de nove protein synthesis, 1999, pp.15, 20~30
- Jermal A, "Cancer statistics", CA Cancer J Clin, 57, pp.43~66 (2007)
- Kawamura K, "Cellular events involved in the sensization of etoposide resistant cells by inhibitors of calcium-calmodulin-dependent processes", Biochem Pharmacol, 52, pp.1903~1909 (1996)
- rr JFR, "Apoptosis. Its significance in cancer and cancer therapy", Cancer, 73, pp.2013~2026 (1994)
- Kerr JFR, "Apoptosis: a basic biological phenomenon with wide range implications in tissue kinetics", Br J Cancer, 26, pp.239~257 (1972)
- Kwasniewsk A, "Frequency of HPV infection and the level of ascorbic acid in serum of women with cervix dysplasia", Med Dosw Mikrobiol, 48, pp.183~188 (1996)
- Kwon EJ, "Study on the apoptosis in human prostate and breast cancer cells", J Korean Cancer Assoc, 31(4), pp.728~738 (1999)
- Kyprianou N, "Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer", World J Urol, 12, pp.299~303 (1994)
- Kyprianou N, "Activation of programmed cell death in the rat ventral prostate after castration", Endocrinology, 122, pp.552~562 (1988)
- Lissoni P, "A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion", Anticancer Res, 25, pp.3597~3599 (2005)
- Lu S, "Molecular mechanism of androgen-independent growth of human prostate cancer LNCaP cells", Endocrinology, 140, pp.5054~5059 (1999)
- McKeage K, "Docetaxel in hormone-refractory metastatic prostate cancer", Drugs, 65, pp.2287~2294 (2005)
- Mimeault M, "Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies", Carcinogenesis, 27, pp.1~22 (2006)
- Mimeault M, "Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide", Int J Cancer, 120, pp.160~169 (2006)
- Okamoto-Kubo S, "Apoptosis induced by etoposide in small-cell lung cancer cell lines", Cancer Chemother Pharmacol, 33, pp.385~390 (1994)
- Penne K, "Gefitinib (Iressa, ZD1839) and tyrosinase inhibitors: the wave of the future in cancer therapy", Cancer Nurs, 28, pp.481~486 (2005)
- Rennie PS, "Cortisol alters gene expression during involution of the rat ventral prostate", Mol Endocrinol, 3, pp.703~708 (1989)
- Ruddy VG, "Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing p53", Biochemical and Biophysical Research Communications, 282, pp.409~415 (2001)
- Salido M, "X-ray microanalysis of etoposide-induced apoptosis in the pc-3 prostate cancer cell line", Cell Biol Int, 25(6), pp.499~508 (2001)
- Sestili P, "Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically atteinable concentrations of ascorbic acid: Cell death prevention by extracellular catalase or catarase from cocultured erythrocytes or fibroblasts", J Pharmacol Exp Ther, 277, pp.1719~1725 (1996)
- Shacter E, "Oxidative stress interferes with cancer chemotherapy: Inhibition of lymphoma cell apoptosis and phagocytosis", Blood, 96, pp.307~313 (2000)
- Skladanowski A, "Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells", Biochem Pharmacol, 46, pp.376~382 (1993)
- Sklar GN, "Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis", J Urol, 150, pp.1526~1532 (1993)
- Smith DC, "Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma", Cancer, 98, pp.269~276 (2003)
- Sumitomo M, "Protein kinase Cδ amplifies ceramide formation via mitochondrial signaling in prostate cancer cells", J Clin Invest, 109, pp.827~836 (2002)
- Tu H, "Incidence of apoptosis and cell proliferation in prostate cancer. Relationship with TGF-beta and bcl-2 expression", Int J Cancer (Pred Oncol), 69, pp.357~363 (1996)
